Home > M&A deals 2009 > Biovail Corp acquires GlaxoSmithKline plc - Wellbutrin XL
Divestiture · Life Science · May 2009

Biovail Corp acquires GlaxoSmithKline plc - Wellbutrin XL

On May 6, 2009, Biovail Corp acquired GlaxoSmithKline plc - Wellbutrin XL, a life science company in United States, from Glaxosmithkline plc.

Deal at a glance

AnnouncedMay 6, 2009 TypeDivestiture TargetGlaxoSmithKline plc - Wellbutrin XL Buyer Biovail Corp Seller Glaxosmithkline plc SectorLife Science LocationUnited States ValueMembers only

Target company

GlaxoSmithKline plc - Wellbutrin XL
United States
Life Sciencesector
-founded
Activestatus
View the company profile →

Buyer

Biovail Corp
Company · 3 deals on record
  • 2nd transaction in life science
  • 1st transaction in United States
3deals, all time
3in this sector
2010latest

Seller

Glaxosmithkline plc
Company · 84 deals on record
84investments
57in this sector
42exits

Members only

Contact details at the buyers and sellers
The full deal history of every party
Co-investors and the other advisors on this deal
Deal value and revenue or EBITDA multiples

Related deals

Orbus Therapeutics, Inc.Same sector and country · Oct 2026
ArtesRx LLCSame sector and country · Aug 2026
Firefly Bio, Inc.Same sector and country · Jul 2026

Questions about this deal

Who acquired GlaxoSmithKline plc - Wellbutrin XL?Biovail Corp acquired GlaxoSmithKline plc - Wellbutrin XL on May 6, 2009.

Who sold GlaxoSmithKline plc - Wellbutrin XL?Glaxosmithkline plc was the seller.

What type of deal was it?It was a divestiture in the life science sector in 2009.

See the full picture on AcquityDataContacts, full deal histories, co-investors and deal values. Free for a day with your Google account, no card needed.
Try it free
Data updated daily on AcquityData (Acquity Data).